ArriBent BioPharma Has Collaborated With Jiangsu Alphamab Biopharmaceuticals, Alphamab Oncology's Subsidiary For Cancer-focused Antibody-drug Conjugates With Upfront And Potential Milestone Payments To Alphamab Of Up To $615.5M
ArriBent BioPharma Has Collaborated With Jiangsu Alphamab Biopharmaceuticals, Alphamab Oncology's Subsidiary For Cancer-focused Antibody-drug Conjugates With Upfront And Potential Milestone Payments To Alphamab Of Up To $615.5M
ArriBent BioPharma已與江蘇阿法馬生物製藥有限公司合作，阿法馬生物製藥的子公司Alphamab Oncology致力於抗癌抗體藥物偶聯物，此合作項目向Alphamab提供最高615.5百萬美元的預付款和潛在的里程碑付款。
ArriBent BioPharma Has Collaborated With Jiangsu Alphamab Biopharmaceuticals, Alphamab Oncology's Subsidiary For Cancer-focused Antibody-drug Conjugates With Upfront And Potential Milestone Payments To Alphamab Of Up To $615.5M
ArriBent BioPharma已與江蘇阿法馬生物製藥有限公司合作，阿法馬生物製藥是阿法馬腫瘤的子公司，專注於癌症相關的抗體藥物聯合治療，預付款和里程碑付款最高可達615.5百萬美元。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。